ENVALITH
WDBココ株式会社 logo

WDB coco CO., LTD.

7079・Growth Market・Services

Official website
WDBココ株式会社 logo
WDB coco CO., LTD.7079

Business

WDB coco CO., LTD. is a specialized CRO (Contract Research Organization) that provides four services—Safety Information Management Service, Document Support Service, Post-Marketing Surveillance Support Service, and Clinical Research Support Service—across the various stages from development through post-marketing for pharmaceutical and medical device companies. Founded in 1984, the company listed on the Tokyo Stock Exchange Mothers market (now the Growth Market) in 2019. Its major clients include leading domestic and overseas pharmaceutical companies such as Chugai Pharmaceutical, GlaxoSmithKline, Eli Lilly Japan, and AbbVie, and it provides services under both outsourcing contracts and staffing dispatch contracts. As a wholly owned subsidiary of WDB Holdings, the company conducts its business while leveraging the human resource base of the parent company group.

Business Model

Based on outsourcing agreements with customer pharmaceutical and medical device companies, the company accumulates revenue by continuously receiving specialized operations centered on safety information management. It aims for growth through two approaches: acquiring additional projects from existing customers and developing new customers. By standardizing and automating business processes, it seeks to improve productivity, using the ordinary income margin as a key KPI to maintain and enhance profitability. Capital expenditures are minor, and the company has a structure that stably generates operating cash flow.

Company Strengths

In FY2026 (ending March 2026), the company secured an ordinary income to net sales ratio of 20.0% even amid a phase of declining profit. From FY2022 (ending March 2022) to FY2025 (ending March 2025), the operating margin recorded a level exceeding 26%, and the company has a flexible cost structure that can limit the extent of profitability deterioration by flexibly optimizing labor costs (curbing overtime work and hiring).

The company has built continuous business relationships with major domestic and overseas pharmaceutical companies, including Chugai Pharmaceutical (25.1% of net sales), GlaxoSmithKline (9.6%), Eli Lilly Japan (8.0%), and AbbVie (7.5%). Additional outsourced projects from existing clients are stably in operation, and the depth of the customer base underpins earnings.

As of the end of FY2026 (ending March 2026), the company held cash and cash equivalents of ¥3,761 million, and maintained a debt-free management structure with net assets of ¥4,782 million against total liabilities of ¥921 million. Operating cash flow generated was ¥570 million, and since the burden of capital investment is light, the company has financial capacity to allocate the majority of free cash flow to shareholder returns and growth investment.

ENVALITH's Perspective

The main cause of the revenue decline in FY2026 (ending March 2026) (down ¥510 million year on year) was a review of outsourced work scope by some clients in the Safety Information Management Service and a decrease in the number of adverse event cases. The FY2027 (ending March 2027) forecast also anticipates a continuation of this trend (net sales of ¥4,655 million, down 3.3% year on year), and determining whether this decline is a temporary fluctuation or a structural contraction in demand is central to investment judgment.

In FY2026 (ending March 2026), the operating margin was 19.9% (down 4.6pt from 24.5% in the previous fiscal year), and the ordinary income margin was 20.0%. While net sales declined 9.6%, labor cost optimization (curbing overtime work and hiring) limited the decline in operating income to 26.7%. For FY2027 (ending March 2027), the company forecasts a 3.3% decline in net sales against a 0.3% increase in operating income, and whether margin recovery through cost management can be achieved is a point of focus.

Given the structure of a single segment dependent on specific clients, the risk that changes in major clients' policies will directly affect business performance continues to exist. As an external factor, price cuts on pharmaceuticals and rising development costs in the pharmaceutical industry support outsourcing demand, while changes in the scope of outsourced work in the CRO market (such as work substitution through AI and automation) could alter the market structure over the medium to long term. The redefinition of the value provided by the Document Support Service and progress in expanding new orders will serve as evaluation axes.

Growth Strategy

Twin-track push to rebuild the CRO model through business standardization and automation while expanding new order intake

In the core Safety Information Management business, the company continued to operate additional outsourced projects for existing customers while acquiring new customers. In FY2026 (ending March 2026), outsourced projects from several new customers contributed to results, but this was insufficient to offset the decline in case volumes at certain existing customers. The company expects the decline in adverse event case numbers to continue in FY2027 (ending March 2027).

The company is promoting the elimination of personnel dependency and the standardization and automation of business processes to improve quality reproducibility and productivity, thereby establishing a competitive advantage. It is currently reviewing the value proposition of its service offerings to capture structural changes in the CRO market (changes in outsourced business scope and approach).

The company has redefined the value proposition of its existing Document Support Service and is presenting proposals to customers based on this redefinition to expand new order intake. It aims to strengthen the competitiveness of its service lines by treating changes in outsourced work within the CRO market as an opportunity.

The company opened the Osaka Operations Center in FY2026 (ending March 2026), resulting in a ¥89 million increase in property, plant and equipment. Through the geographic expansion of its supply structure, the company aims to enhance its ability to respond to customers and build a foundation for acquiring new orders.

Last updated: July 19, 2026